Literature DB >> 1405316

Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells.

B Memoli1, C Libetta, T Rampino, A Dal Canton, G Conte, G Scala, M R Ruocco, V E Andreucci.   

Abstract

Interleukin-6 (IL-6) has a complex spectrum of biological activities, for example, growth and differentiation of B cells and synthesis of acute-phase proteins by the liver. To evaluate the role of this cytokine in the inflammatory response induced by blood interaction with hemodialysis membranes, we have investigated the IL-6 synthesis and release in supernatant of 24-hour cultured peripheral blood mononuclear cells (PBMC) isolated from: (a) 10 hemodialyzed patients, (b) seven patients with advanced chronic renal failure (GFR less than or equal to 10 ml/min), and (c) eight healthy control subjects. In the same groups of subjects we evaluated the relationship between IL-6 synthesis and release and beta-2-microglobulin (beta 2m) production. Before and after dialytic treatment hemodialysis patient blood samples were drawn using the following criteria: (1) after two months of dialysis with cuprophan membranes, (2) after one and two months of dialysis with polymethylmethacrylate (PMMA) membranes, and finally, (3) after one further month of dialysis with cuprophan membranes. IL-6 was determined after 72 hours of incubation of PBMC supernatant serial dilutions with IL-6-dependent hybridoma cell line, 7TD1. Compared to IL-6 synthesis in control subjects (6.0 +/- 5.6 U/3 x 10(6) PBMC/24 hr), hemodialyzed patients, when treated with cuprophan membranes, showed significantly higher value of IL-6 production both before (23 +/- 13 U/3 x 10(6) PBMC/24 hr) and after (26.2 +/- 11.3 U/3 x 10(6) PBMC/24 hr) the dialytic session.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1405316     DOI: 10.1038/ki.1992.292

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  Sonographic findings in haemodialysis-related chronic arthropathy.

Authors:  G Coari; A Iagnocco; S Maggi; M Bracci; A De Cata; M Mastantuono; M Larciprete; S Persichetti
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

Review 2.  Effects of Medium Cut-Off Polyarylethersulfone and Polyvinylpyrrolidone Blend Membrane Dialyzers in Hemodialysis Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Yu-Hui Hung; Tai-Shuan Lai; Mohamed Belmouaz; Ya-Chun Tu; Chun-Fu Lai; Shuei-Liong Lin; Yung-Ming Chen
Journal:  Membranes (Basel)       Date:  2022-04-20

Review 3.  Water quality in conventional and home haemodialysis.

Authors:  Matthew J Damasiewicz; Kevan R Polkinghorne; Peter G Kerr
Journal:  Nat Rev Nephrol       Date:  2012-10-23       Impact factor: 28.314

Review 4.  Fatigue in patients receiving maintenance dialysis: a review of definitions, measures, and contributing factors.

Authors:  Manisha Jhamb; Steven D Weisbord; Jennifer L Steel; Mark Unruh
Journal:  Am J Kidney Dis       Date:  2008-06-24       Impact factor: 8.860

5.  Alteration of HDL Protein Composition with Hemodialysis Initiation.

Authors:  Ke Wang; Leila R Zelnick; Andrew N Hoofnagle; Tomas Vaisar; Clark M Henderson; Peter B Imrey; Cassianne Robinson-Cohen; Ian H de Boer; Yan-Ting Shiu; Jonathan Himmelfarb; Gerald J Beck; Bryan Kestenbaum
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-25       Impact factor: 8.237

Review 6.  Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.

Authors:  Christos P Argyropoulos; Shan Shan Chen; Yue-Harn Ng; Maria-Eleni Roumelioti; Kamran Shaffi; Pooja P Singh; Antonios H Tzamaloukas
Journal:  Front Med (Lausanne)       Date:  2017-06-15

7.  Immunomodulatory effect of continuous venovenous hemofiltration during sepsis: preliminary data.

Authors:  Giuseppe Servillo; Maria Vargas; Antonio Pastore; Alfredo Procino; Michele Iannuzzi; Alfredo Capuano; Andrea Memoli; Eleonora Riccio; Bruno Memoli
Journal:  Biomed Res Int       Date:  2013-07-23       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.